Literature DB >> 3840228

Substrate-product relation of 1-hydroxylase activity in primary hyperparathyroidism.

V LoCascio, S Adami, G Galvanini, M Ferrari, L Cominacini, D Tartarotti.   

Abstract

The synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH)2D), is thought to be relatively insensitive to the serum concentration of its precursor, 25-hydroxyvitamin D (25-OH-D). We compared the effect of oral administration of 25-OH-D3 (50 micrograms per day for one month) on serum concentrations of calcium, phosphate, parathyroid hormone, 25-OH-D, and 1,25-(OH)2D in five healthy adults and in six patients with primary hyperparathyroidism. In normal adults the mean (+/- S.D.) serum level of 25-OH-D rose from 18 +/- 9 to 136 +/- 47 ng per milliliter; no significant changes were observed in the other serum levels. In contrast, comparable increases in the levels of circulating 25-OH-D in patients with primary hyperparathyroidism caused a consistent slight rise in serum calcium and phosphate levels, a partial suppression of parathyroid hormone, and a sharp increase in the level of 1,25-(OH)2D. During this period a significant positive correlation was found between serum concentrations of 25-OH-D and 1,25-(OH)2D (P less than 0.001). These results provide evidence that in patients with primary hyperparathyroidism, levels of circulating 1,25-(OH)2D may be more dependent on the prevailing serum concentrations of 25-OH-D than they are in normal adults.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840228     DOI: 10.1056/NEJM198510313131804

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  3 in total

1.  Orthopaedic . radiology . pathology conference: Chronic multifocal chest and leg pain in a 34-year-old woman.

Authors:  Adam M Kaufman; John A Abraham; Susan V Kattapuram; Francis J Hornicek
Journal:  Clin Orthop Relat Res       Date:  2008-09-23       Impact factor: 4.176

2.  Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

Authors:  R Cesareo; E Di Stasio; F Vescini; G Campagna; R Cianni; V Pasqualini; F Romitelli; F Grimaldi; S Manfrini; A Palermo
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

3.  Renal stone disease, elevated iPTH level and normocalcemia.

Authors:  Nada B Dimkovic; Abdul Aziz Wallele; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.